| Authors |
Oerlemans, Simone ; Efficace, Fabio ; Shamieh, Omar ; Borges, Fabio Cardoso ; de Jong, Corine ; Dong, Dong ; Lehmann, Jens ; Malak, Sandra ; Petranovic, Duska ; Scholz, Christian W ; Caocci, Giovanni ; Molica, Stefano ; Griškevičius, Laimonas ; Nagele, Eva ; Bredart, Anne ; Carvalho, Elisabete ; Xochelli, Aliki ; van Rentergem, Joost Agelink ; Alrjoob, Waleed ; Mueller, Anja ; Freitas, Ana Carolina ; Cocks, Kim ; Creutzberg, Carien ; Kyriakou, Charalampia ; van de Poll-Franse, Lonneke |
| Abstract [eng] |
Hodgkin lymphoma (HL) has become 1 of the most curable cancers. Therefore, rigorous assessment of health-related quality of life (HRQoL) and symptom burden of these patients is essential to support informed clinical decisions. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group previously developed the EORTC Quality of Life Questionnaire (QLQ) Hodgkin Lymphoma 27. This paper reports the final results of an international study by the EORTC group to develop a HRQoL disease-specific measure for these patients: the EORTC QLQ-HL27. Patients with a confirmed diagnosis of HL (N = 381) were enrolled from 12 countries and completed the EORTC QLQ-C30, QLQ-HL27, and a debriefing questionnaire at baseline (any time after diagnosis). A subset completed a retest (n = 126) or responsiveness-to-change analyses (RCA) second measurement (n = 98). Psychometrics were evaluated. Confirmatory factor analysis showed an acceptable fit of the 27 items of the QLQ-HL27 on its 4 scales (symptom burden, physical condition/fatigue, emotional impact, and worries about health/functioning). Test–retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results. Symptom burden and fatigue was higher among patients on treatment (with 36%-83% reporting at least a few problems) compared with those who had completed treatment (19%-61% reporting at least a few problems). Prevalence of worries about health and functioning (reporting at least some worry) was similar for patients on treatment (51%-81%) vs those who had completed treatment (52%-78%). Implementation of the EORTC QLQ-HL27 in research and clinical applications will increase sensitivity of HRQoL assessment in patients with HL. High quality data generated through use of this questionnaire are expected to facilitate clinical decision making in the HL setting. |
